[Featured Stock] Jinwon Life Sciences Hits New High Following Oral COVID-19 Treatment Variant Efficacy Announcement

[Asia Economy Reporter Ji Yeon-jin] Jinwon Life Sciences announced that its oral (pill) COVID-19 treatment candidate showed effectiveness against both the early pandemic virus and variant viruses in animal experiments, causing its stock to surge and reach a new 52-week high.

As of 10 a.m. on the 30th, Jinwon Life Sciences was traded at 49,600 KRW on the KOSPI market, up 25.25% from the previous day. This is a 52-week high.

The company stated that when the COVID-19 candidate substance GLS-1027 was administered in increased doses to a hamster aggressive infection model that induces severe COVID-19 pneumonia, pneumonia symptom indicators decreased.

These results were confirmed in infection models of both the early pandemic COVID-19 virus and the Beta variant virus originating from South Africa.

Jinwon Life Sciences received approval from the U.S. Food and Drug Administration (FDA) last November for the Phase 2 clinical trial plan of GLS-1027, which is currently being conducted in the U.S. and Puerto Rico, with plans to initiate trials in North Macedonia and Bulgaria. In February of this year, the company also submitted a clinical trial plan to the Korean Ministry of Food and Drug Safety. GLS-1027 is an oral small molecule drug that inhibits cytokines, which are inflammation-inducing substances.

This content was produced with the assistance of AI translation services.